Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Radiology|January 1, 1997
Radiological features of the visceral and skeletal involvement of hemochromatosisH J Jäger, U Mehring, G F Götz, et al.
Leukemia Research|March 27, 2018
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trialsWolfgang Knauf, Ali Aldaoud, Christoph Losem, et al.
Breast Care (Basel, Switzerland)|June 15, 2017
Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver VariationJulian Puppe, Deborah van Ooyen, Jeanne Neise, et al.
The Oncologist|July 3, 2007
Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumorsTilman Steinmetz, Martin Hellmich, Michael Neise, et al.
Clinical Chemistry and Laboratory Medicine|June 5, 2013
Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsTilman Steinmetz, Kathrin Kuhr, Uwe Totzke, et al.
BMC Cancer|January 6, 2010
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancerJens Huober, Werner Fett, Arnd Nusch, et al.
Drug Design, Development and Therapy|March 6, 2014
Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot studyJochen G Mainz, Katja Schädlich, Claudia Schien, et al.
Journal of Cancer Research and Clinical Oncology|September 2, 2008
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphomaP Schütt, K Zimmermann, C Derks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphomaMathias J Rummel, Salah E Al-Batran, Soo-Z Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaJoerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
Pageof 4